Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1265-1272

  He, Yan Ling ^a   Sabo, Ron ^b   Picard, Franck ^b   Wang, Yibin ^b   Herron, Jerry ^c   Ligueros Saylan, Monica ^b   Dole, William P ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Arkansas Research Medical Testing LLC   (United States)

Author keywords

DPP 4 inhibitor; Drug drug interactions; Metformin; Type 2 diabetes; Vildagliptin

Indexed keywords

METFORMIN; VILDAGLIPTIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKLE EDEMA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; LEG EDEMA; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; SIDE EFFECT; XEROSTOMIA;

ADAMANTANE; ADULT; AGED; ALGORITHMS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES;

EID: 67649398908     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902869102     Document Type: Article

References (25)

1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
2. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
3. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-698 (Pubitemid 41601073)
4. Lauster CD, McKaveney TP, Muench SV. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm 2007;64:1265-1273 (Pubitemid 47216194)
5. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007;46:577-588 (Pubitemid 47025358)
6. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-4894 (Pubitemid 41159387)
7. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-2084 (Pubitemid 38619835)
8. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007;46:787-802 (Pubitemid 47347450)
9. Dejager S, Razac S, Foley J, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-223 (Pubitemid 46580622)
10. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-138 (Pubitemid 46240373)
11. Bailey CJ. Metformin-an update. Gen Pharmacol 1993;24:1299-1309
12. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-1894 (Pubitemid 37108399)
13. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004;17:336-342
14. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004;324:92-97 (Pubitemid 39311464)
15. Williams EJ. Experimental designs balanced for the estimation of residual effects of treatment. Australian Journal of Scientific Research 1949;Ser. A2:149-168
16. Glucophage Prescribing Information. Bristol-Myers Squibb Company, Princeton, NJ, USA. Revised June 2006
17. He YL, Ligueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008;48:85-95 (Pubitemid 350292271)
18. Serra D, He YL, Bullock J, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes. Int J Clin Pharmacol Ther 2008;46:349-364 (Pubitemid 352005928)
19. Schweizer A, Couturier A, Foley J, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007;24:955-961 (Pubitemid 47301637)
20. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:675-682 (Pubitemid 352044298)
21. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:1114-1124
22. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-371 (Pubitemid 26177181)
23. He YL, Sabo R, Balez S, et al. Absolute bioavailability of vildagliptin in healthy subjects. Clin Pharmacol Ther 2006;79:P38
24. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-895 (Pubitemid 46556583)
25. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24- week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90 (Pubitemid 350302434)